PH-sensitive Pt nanocluster assembly overcomes cisplatin resistance and heterogeneous stemness of hepatocellular carcinoma

ACS Central Science

Volumn 2, Issue 11, 2016, Pages 802-811

  Xia, Hongping ^a,c   Li, Fangyuan ^a,b   Hu, Xi ^a   Park, Wooram ^f   Wang, Shuaifei ^a   Jang, Youngjin ^d,e   Du, Yang ^a   Baik, Seungmin ^d,e   Cho, Soojeong ^f   Kang, Taegyu ^d,e   Kim, Dong Hyun ^f   Ling, Daishun ^a,b   Hui, Kam Man ^c,g   Hyeon, Taeghwan ^d,e  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^d Institute for Basic Science   (South Korea)

^e Seoul National University   (South Korea)

^f NORTHWESTERN UNIVERSITY   (United States)

^g DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; NANOCLUSTERS; PH SENSORS;

CHEMORESISTANCE; CISPLATIN RESISTANCES; HEPATOCELLULAR CARCINOMA; PERIPHERAL BLOOD; PH SENSITIVE POLYMERS; PT NANOCLUSTERS; SUBCELLULAR COMPARTMENTS; TARGETING PEPTIDES;

PLATINUM;

EID: 85016853331     PISSN: 23747943     EISSN: 23747951     Source Type: Journal    
DOI: 10.1021/acscentsci.6b00197     Document Type: Article

References (68)

1. Maluccio, M.; Covey, A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. Ca-Cancer J. Clin. 2012, 62, 394-399.
2. European Association For The Study of The Liver. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 2012, 56, 908-943.
3. Bruix, J.; Takayama, T.; Mazzaferro, V.; Chau, G.-Y.; Yang, J.; Kudo, M.; Cai, J.; Poon, R. T.; Han, K.-H.; Tak, W. Y.; et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015, 16, 1344-1354.
4. Yu, F.; Yao, H.; Zhu, P.; Zhang, X.; Pan, Q.; Gong, C.; Huang, Y.; Hu, X.; Su, F.; Lieberman, J.; Song, E. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131, 1109-1123.
5. Wei, X.; Dombkowski, D.; Meirelles, K.; Pieretti-Vanmarcke, R.; Szotek, P. P.; Chang, H. L.; Preffer, F. I.; Mueller, P. R.; Teixeira, J.; MacLaughlin, D. T.; Donahoe, P. K. Müllerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics. Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 18874-18879.
6. Bertolini, G.; Roz, L.; Perego, P.; Tortoreto, M.; Fontanella, E.; Gatti, L.; Pratesi, G.; Fabbri, A.; Andriani, F.; Tinelli, S.; et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 16281-16286.
7. Lee, T. K. W.; Castilho, A.; Cheung, V. C. H.; Tang, K. H.; Ma, S.; Ng, I. O. L. CD24+ liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell 2011, 9, 50-63.
8. Kim, B. Y. S.; Rutka, J. T.; Chan, W. C. W. Nanomedicine. N. Engl. J. Med. 2010, 363, 2434-2443.
9. Mout, R.; Moyano, D. F.; Rana, S.; Rotello, V. M. Surface functionalization of nanoparticles for nanomedicine. Chem. Soc. Rev. 2012, 41, 2539-2544.
10. Farokhzad, O. C.; Langer, R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3, 16-20.
11. Barry, N. P. E.; Sadler, P. J. Challenges for metals in medicine: how nanotechnology may help to shape the future. ACS Nano 2013, 7, 5654-5659.
12. Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2, 751-760.
13. Krishnamurthy, S.; Ke, X.; Yang, Y. Y. Delivery of therapeutics using nanocarriers for targeting cancer cells and cancer stem cells. Nanomedicine 2015, 10, 143-160.
14. Yoshii, T.; Geng, Y.; Le, N. D. B.; Goel, H. L.; Mercurio, A. M.; Rotello, V. M. Highlights from the latest articles in nanomaterial-based therapies for targeting cancer stem cells. Nanomedicine 2015, 10, 3427-3429.
15. Asharani, P. V.; Xinyi, N.; Hande, M. P.; Valiyaveettil, S. DNA damage and p53-mediated growth arrest in human cells treated with platinum nanoparticles. Nanomedicine 2010, 5, 51-64.
16. Barone, M.; Sciortino, M. T.; Zaccaria, D.; Mazzaglia, A.; Sortino, S. Nitric oxide photocaging platinum nanoparticles with anticancer potential. J. Mater. Chem. 2008, 18, 5531-5536.
17. Chien, C.-T.; Yan, J. Y.; Chiu, W.-C.; Wu, T. H.; Liu, C. Y.; Lin, S. Y. Caged Pt nanoclusters exhibiting corrodibility to exert tumorinside activation for anticancer chemotherapeutics. Adv. Mater. 2013, 25, 5067-5073.
18. Gao, J.; Liang, G.; Zhang, B.; Kuang, Y.; Zhang, X.; Xu, B. FePt@CoS2 yolk-shell nanocrystals as a potent agent to kill HeLa cells. J. Am. Chem. Soc. 2007, 129, 1428-1433.
19. Mironava, T.; Simon, M.; Rafailovich, M. H.; Rigas, B. Platinum folate nanoparticles toxicity: cancer vs. normal cells. Toxicol. In Vitro 2013, 27, 882-889.
20. Pelka, J.; Gehrke, H. M.; Turk, M.; Crone, M.; Brase, S.; Muller, T.; Blank, H.; Send, W.; Zibat, V.; Brenner, P.; Esselen, M.; Schneider, R.; Gerthsen, D.; Marko, D. Cellular uptake of platinum nanoparticles in human colon carcinoma cells and their impact on cellular redox systems and DNA integrity. Chem. Res. Toxicol. 2009, 22, 649-659.
21. Porcel, E.; Liehn, S.; Remita, H.; Usami, N.; Kobayashi, K.; Furusawa, Y.; Le Sech, C.; Lacombe, S. Platinum nanoparticles: a promising material for future cancer therapy? Nanotechnology 2010, 21, 085103.
22. Shiny, P. J.; Mukherjee, A.; Chandrasekaran, N. DNA damage and mitochondria-mediated apoptosis of A549 lung carcinoma cells induced by biosynthesised silver and platinum nanoparticles. RSC Adv. 2016, 6, 27775-27787.
23. Teow, Y.; Valiyaveettil, S. Active targeting of cancer cells using folic acid-conjugated platinum nanoparticles. Nanoscale 2010, 2, 2607-2613.
24. Xue, X.; Hall, M. D.; Zhang, Q.; Wang, P. C.; Gottesman, M. M.; Liang, X. J. Nanoscale drug delivery platforms overcome platinumbased resistance in cancer cells due to abnormal membrane protein trafficking. ACS Nano 2013, 7, 10452-10464.
25. Kim, B. H.; Hackett, M. J.; Park, J.; Hyeon, T. Synthesis, characterization, and application of ultrasmall nanoparticles. Chem. Mater. 2014, 26, 59-71.
26. Sakurai, T.; Shibata, M.; Horiuchi, R.; Yagi, I.; Kondo, T. Study of platinum dissolution mechanism using a highly sensitive electrochemical quartz crystal microbalance. Chem. Lett. 2011, 40, 402-404.
27. Hartmann, J. T.; Lipp, H. P. Toxicity of platinum compounds. Expert Opin. Pharmacother. 2003, 4, 889-901.
28. Florea, A. M.; Büsselberg, D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers 2011, 3, 1351-1371.
29. Nie, Z.; Petukhova, A.; Kumacheva, E. Properties and emerging applications of self-assembled structures made from inorganic nanoparticles. Nat. Nanotechnol. 2010, 5, 15-25.
30. He, L.; Wang, M.; Ge, J.; Yin, Y. Magnetic assembly route to colloidal responsive photonic nanostructures. Acc. Chem. Res. 2012, 45, 1431-1440.
31. Stolarczyk, J. K.; Deak, A.; Brougham, D. F. Nanoparticle clusters: assembly and control over internal order, current capabilities, and future potential. Adv. Mater. 2016, 28, 5400-5424.
32. Lee, H.; Sun, E.; Ham, D.; Weissleder, R. Chip-NMR biosensor for detection and molecular analysis of cells. Nat. Med. 2008, 14, 869-874.
33. Rosi, N. L.; Mirkin, C. A. Nanostructures in biodiagnostics. Chem. Rev. 2005, 105, 1547-1562.
34. Jin, Y.; Gao, X. Plasmonic fluorescent quantum dots. Nat. Nanotechnol. 2009, 4, 571-576.
35. Pan, Y.; Du, X.; Zhao, F.; Xu, B. Magnetic nanoparticles for the manipulation of proteins and cells. Chem. Soc. Rev. 2012, 41, 2912-2942.
36. Zagorovsky, K.; Chan, W. C. W. A plasmonic DNAzyme strategy for point-of-care genetic detection of infectious pathogens. Angew. Chem., Int. Ed. 2013, 52, 3168-3171.
37. Taton, T. A.; Mirkin, C. A.; Letsinger, R. L. Scanometric DNA array detection with nanoparticle probes. Science 2000, 289, 1757-1760.
38. Ohta, S.; Glancy, D.; Chan, W. C. W. DNA-controlled dynamic colloidal nanoparticle systems for mediating cellular interaction. Science 2016, 351, 841-845.
39. Li, H.-J.; Du, J.-Z.; Du, X.-J.; Xu, C.-F.; Sun, C.-Y.; Wang, H.-X.; Cao, Z.-T.; Yang, X.-Z.; Zhu, Y.-H.; Nie, S.; Wang, J. Stimuliresponsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy. Proc. Natl. Acad. Sci. U. S. A. 2016, 113, 4164-4169.
40. Sun, Q.; Sun, X.; Ma, X.; Zhou, Z.; Jin, E.; Zhang, B.; Shen, Y.; Van Kirk, E. A.; Murdoch, W. J.; Lott, J. R.; et al. Integration of nanoassembly functions for an effective delivery cascade for cancer drugs. Adv. Mater. 2014, 26, 7615-7621.
41. Ling, D.; Park, W.; Park, S.-J.; Lu, Y.; Kim, K. S.; Hackett, M. J.; Kim, B. H.; Yim, H.; Jeon, Y. S.; Na, K.; Hyeon, T. Multifunctional tumor pH-sensitive self-assembled nanoparticles for bimodal imaging and treatment of resistant heterogeneous tumors. J. Am. Chem. Soc. 2014, 136, 5647-5655.
42. Lok, C. N.; Zou, T.; Zhang, J. J.; Lin, W. S.; Che, C. M. Controlled-release systems for metal-based nanomedicine: encapsulated/self-assembled nanoparticles of anticancer gold(III)/platinum-(II) complexes and antimicrobial silver nanoparticles. Adv. Mater. 2014, 26, 5550-5557.
43. Ashley, C. E.; Carnes, E. C.; Phillips, G. K.; Padilla, D.; Durfee, P. N.; Brown, P. A.; Hanna, T. N.; Liu, J.; Phillips, B.; Carter, M. B.; et al. The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat. Mater. 2011, 10, 389-397.
44. Fang, J.; Nakamura, H.; Maeda, H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Delivery Rev. 2011, 63, 136-151.
45. Owens, D. E., III; Peppas, N. A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 2006, 307, 93-102.
46. Wang, Y.; Zhou, K.; Huang, G.; Hensley, C.; Huang, X.; Ma, X.; Zhao, T.; Sumer, B. D.; DeBerardinis, R. J.; Gao, J. A nanoparticlebased strategy for the imaging of a broad range of tumours by nonlinear amplification of microenvironment signals. Nat. Mater. 2014, 13, 204-212.
47. Ling, D.; Hackett, M. J.; Hyeon, T. Cancer imaging: lighting up tumours. Nat. Mater. 2014, 13, 122-124.
48. Nichols, J. W.; Bae, Y. H. Odyssey of a cancer nanoparticle: from injection site to site of action. Nano Today 2012, 7, 606-618.
49. Sambhy, V.; Macbride, M. M.; Peterson, B. R.; Sen, A. Silver bromide nanoparticle/polymer composites: dual action tunable antimicrobial materials. J. Am. Chem. Soc. 2006, 128, 9798-9808.
50. Loher, S.; Schneider, O. D.; Maienfisch, T.; Bokorny, S.; Stark, W. J. Micro-organism-triggered release of silver nanoparticles from biodegradable oxide carriers allows preparation of self-sterilizing polymer surfaces. Small 2008, 4, 824-832.
51. Dobrovolskaia, M. A.; Patri, A. K.; Zheng, J.; Clogston, J. D.; Ayub, N.; Aggarwal, P.; Neun, B. W.; Hall, J. B.; McNeil, S. E. Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. Nanomedicine 2009, 5, 106-117.
52. Aggarwal, P.; Hall, J. B.; McLeland, C. B.; Dobrovolskaia, M. A.; McNeil, S. E. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv. Drug Delivery Rev. 2009, 61, 428-437.
53. Yezhelyev, M. V.; Qi, L.; O'Regan, R. M.; Nie, S.; Gao, X. Proton-sponge coated quantum dots for siRNA delivery and intracellular imaging. J. Am. Chem. Soc. 2008, 130, 9006-9012.
54. Davis, M. E.; Shin, D. M.; Chen, Z. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discovery 2008, 7, 771-782.
55. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 2000, 92, 1295-1302.
56. Wu, B.; Dröge, P.; Davey, C. A. Site selectivity of platinum anticancer therapeutics. Nat. Chem. Biol. 2008, 4, 110-112.
57. Corde, S.; Biston, M. C.; Elleaume, H.; Esteve, F.; Charvet, A. M.; Joubert, A.; Ducros, V.; Bohic, S.; Simionovici, A.; Brochard, T.; et al. Lack of cell death enhancement after irradiation with monochromatic synchrotron X rays at the K-shell edge of platinum incorporated in living SQ20B human cells as cis-diamminedichlor-oplatinum (II). Radiat. Res. 2002, 158, 763-770.
58. Ciccarelli, R. B.; Solomon, M. J.; Varshavsky, A.; Lippard, S. J. In vivo effects of cis- and trans-diamminedichlor-oplatinum(II) on SV40 chromosomes: differential repair, DNA-protein cross-linking, and inhibition of replication. Biochemistry 1985, 24, 7533-7540.
59. Golebiewska, A.; Brons, N. H. C.; Bjerkvig, R.; Niclou, S. P. Critical appraisal of the side population assay in stem cell and cancer stem cell research. Cell Stem Cell 2011, 8, 136-147.
60. Marquardt, J. U.; Raggi, C.; Andersen, J. B.; Seo, D.; Avital, I.; Geller, D.; Lee, Y. H.; Kitade, M.; Holczbauer, A.; Gillen, M. C.; et al. Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways. Hepatology 2011, 54, 1031-1042.
61. Ling, D.; Xia, H.; Park, W.; Hackett, M. J.; Song, C.; Na, K.; Hui, K. M.; Hyeon, T. pH-sensitive nanoformulated triptolide as a targeted therapeutic strategy for hepatocellular carcinoma. ACS Nano 2014, 8, 8027-8039.
62. Urien, S.; Brain, E.; Bugat, R.; Pivot, X.; Lochon, I.; Van, M. L.; Vauzelle, F.; Lokiec, F. Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients. Cancer Chemother. Pharmacol. 2005, 55, 55-60.
63. Vermorken, J. B.; van der Vijgh, W. J.; Klein, I.; Hart, A. A.; Gall, H. E.; Pinedo, H. M. Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin. Cancer Treat. Rep. 1984, 68, 505-513.
64. Yu, H.; Tang, Z.; Zhang, D.; Song, W.; Zhang, Y.; Yang, Y.; Ahmad, Z.; Chen, X. Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly (L-glutamic acid)-g-methoxy poly-(ethylene glycol) complex nanoparticles for tumor therapy. J. Controlled Release 2015, 205, 89-97.
65. Paraskar, A.; Soni, S.; Basu, S.; Amarasiriwardena, C. J.; Lupoli, N.; Srivats, S.; Roy, R. S.; Sengupta, S. Rationally engineered polymeric cisplatin nanoparticles for improved antitumor efficacy. Nanotechnology 2011, 22, 265101-265108.
66. Zhang, Y. N.; Poon, W.; Tavares, A. J.; McGilvray, I. D.; Chan, W. C. W. Nanoparticle-liver interactions: Cellular uptake and hepatobiliary elimination. J. Controlled Release 2016, DOI: 10.1016/j.jconrel.2016.01.020.
67. Xia, H.; Chen, J.; Shi, M.; Gao, H.; Sekar, K.; Seshachalam, V. P.; Ooi, L. L. P. J.; Hui, K. M. EDIL3 is a novel regulator of epithelialmesenchymal transition controlling early recurrence of hepatocellular carcinoma. J. Hepatol. 2015, 63, 863-873.
68. Feng, G.-S. Conflicting roles of molecules in hepatocarcinogenesis: paradigm or paradox. Cancer Cell 2012, 21, 150-154.